Q: Hi 5i team!
What is your opinion of HLS these days?
I last asked about them in Feb 2019. At the time you were concerned about their debt level. Has it improved (marginally or otherwise) since then or do you foresee any further improvement in 2020 and beyond based on their recent financials?
They had a good 2019 wrt stock price appreciation.
They have recently received approval from Health Canada re Vascepa but significant sales from that drug may not occur for a year or 2 (or more).
Can this be added to an already diversified portfolio of mid caps? I recently took a 1/4 position in mid Dec at $19.34. I would like to add a further 1/4 position each quarter going forward. This will allow me to monitor their overall progress wrt their additional drug portfolio.
They stated that peak sales of Vascepa may not occur until 2-4 years thus the patient accumulation.
Cheers,
Steve
What is your opinion of HLS these days?
I last asked about them in Feb 2019. At the time you were concerned about their debt level. Has it improved (marginally or otherwise) since then or do you foresee any further improvement in 2020 and beyond based on their recent financials?
They had a good 2019 wrt stock price appreciation.
They have recently received approval from Health Canada re Vascepa but significant sales from that drug may not occur for a year or 2 (or more).
Can this be added to an already diversified portfolio of mid caps? I recently took a 1/4 position in mid Dec at $19.34. I would like to add a further 1/4 position each quarter going forward. This will allow me to monitor their overall progress wrt their additional drug portfolio.
They stated that peak sales of Vascepa may not occur until 2-4 years thus the patient accumulation.
Cheers,
Steve
